Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin

References

• American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care 2014;37(1 Suppl):S14-80
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Hayes AJ, Leal J, Gray AM, et al. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 2013;56:1925-33
   PubMed Web of Science ®Google Scholar
• Inzucchi S, Bergenstal R, Buse J, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
   PubMed Web of Science ®Google Scholar
• Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90
   PubMed Web of Science ®Google Scholar
• Nauck M, Frid A, Hermansen K, et al. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab 2013;15:204-12
   PubMed Web of Science ®Google Scholar
• Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011;65:397-407
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-56
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59
   PubMed Web of Science ®Google Scholar
• Little RR, Rohlfing CL, Sacks DB. National Glycohemoglobin Standardization Program Steering C, Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem 2011;57:205-14
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Ekstrom N, Miftaraj M, Svensson AM, et al. Glucose-lowering treatment and clinical results in 163,121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register. Diabetes Obes Metab 2012;14:717-26
   Google Scholar
• Nationella diabetesregistret NDR. Nationella diabetesregistret. Årsrapport 2012 års resultat [The Swedish National Diabetes Registry. Annual report Results from year 2012]. Göteborg: Registercentrum Västra Götaland, 2013
   Google Scholar
• Davies MJ, Chubb BD, Smith IC, et al. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabetic Med J Br Diabetic Assoc 2012;29:313-20
   PubMed Web of Science ®Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30
   PubMed Web of Science ®Google Scholar
• Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes 2013;11:90
   PubMed Web of Science ®Google Scholar
• Geelhoed-Duijvestijn PH, Pedersen-Bjergaard U, Weitgasser R, et al. Effects of patient-reported non-severe hypoglycemia on healthcare resource use, work-time loss, and wellbeing in insulin-treated patients with diabetes in seven European countries. J Med Econ 2013;16:1453-61
   PubMedGoogle Scholar
• Gerdtham U, Clarke P, Hayes A, et al. Estimating the cost of diabetes mellitus-related events from inpatient admissions in Sweden using administrative hospitalization data. Pharmacoeconomics 2009;27:81-90
   PubMed Web of Science ®Google Scholar
• Jonsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health J Int Soc Pharmacoecon Outcomes Res 2006;9:193-8
   Google Scholar
• Persson U, Willis M, Odegaard K. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. Eur J Health Econ HEPAC 2010;11:195-203
   PubMed Web of Science ®Google Scholar
• Prompers L, Huijberts M, Schaper N, et al. Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study. Diabetologia 2008;51:1826-34
   PubMed Web of Science ®Google Scholar
• Apotektet. Produkter [Products]. Available at: http://www.apoteket.se/privatpersoner/sidor/start.aspx. Apoteket, 2013
   Google Scholar
• Statens beredning för medicinsk utvärdering (SBU), Egna mätningar av blodglukos vid diabetes utan insulinbehandling. En systematisk litteraturöversikt. Stockholm: SBU, 2009
   Google Scholar
• Sveriges kommuner och landsting. KPP-databasen, 2011. Available at: http://www.skl.se/vi_arbetar_med/statistik/kostnad-per-patient Stockholm, Sweden: Sveriges kommuner och landsting.
   Google Scholar
• Södra regionvårdsnämnden. Regionala priser och ersättningar för södra sjukvårdsregionen 2013. Lund, Sweden: Södra regionvårdsnämnden, 2012
   Google Scholar
• Tandvårds- och läkemedelsförmånsverket (TLV) [Dental and pharmaceutical benefits board]. Databas för beslut [Database for decisions]. Stockholm, Sweden: Tandvårds- och läkemedelsförmånsverket (TLV) [Dental and pharmaceutical benefits board], 2013. Available at: http://www.tlv.se/
   Google Scholar
• Ekman M. Consumption and production by age in Sweden. In: Ekman M, ed. Basic facts and health economic implications in Studies in health economics: modelling and data analysis of costs and survival. Stockholm, Sweden: Stockholm School of Economics; 2002
   Google Scholar
• Östensson CG, Geelhoed-Duijvestijn P, Lahtela J, et al. Self-reported non-severe hypoglycaemic events in Europe. Diabetic med j Br Diabetic Assoc 2013;31:92-101
   Google Scholar
• Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007;30:1638-46
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Mount Hood 5 Modeling Group, Clarke P, et al. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value Health 2013;16:670-85
   PubMed Web of Science ®Google Scholar
• Willis M, Asseburg C, He J. Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM). J Med Econ 2013;16:1007-21
   PubMedGoogle Scholar
• Kiadaliri AA, Gerdtham U-G, Nilsson P, et al. Towards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish Register Data. PLoS ONE 2013;8:e62650
   Google Scholar